DNAe Insights: Exploring the potential economic impact of a rapid, whole‑blood, sample‑to‑report NGS platform for BSI detection

DNAe’s BSI/AMR test on the LiDia‑SEQ™ platform promises clinicians a true sample‑to‑report NGS diagnostic – delivering comprehensive results dramatically faster than today’s blood culture‑dependent standard of care. Download our latest DNAe Insights article to discover how speeding pathogen and AMR identification in suspected BSI or sepsis could save up to $9K per patient and improve management through earlier targeted or de‑escalated antimicrobial therapy — reducing delays, inappropriate treatment, and prolonged hospital stays.